Cardiovascular system medicine sales in Australia stood at 2.23 billion Australian dollars in 2023. Over the past decade, sales experienced a general decline from 2013 to 2017, followed by a recovery phase starting in 2018. From 2021 to 2023, the market showed consistent year-on-year growth of over 3.9%. The compound annual growth rate (CAGR) from 2018 to 2023 was 4.16%. Looking ahead, the forecast for 2024 to 2028 projects a 2.11% annual growth rate, suggesting stable but moderated growth compared to recent years. The estimated overall growth rate during this period is 11.02%.

Future trends to watch for include:

Innovations in cardiovascular treatments and personalized medicine could drive market growth.
Health policy changes impacting drug pricing and reimbursement could affect market dynamics.
Increasing prevalence of cardiovascular diseases due to aging population and lifestyle factors may boost demand.
Emerging competition from new market entrants or generic medicines could alter market share and pricing.